For instance, one randomized clinical trial reported that PACAP-38 infusion induced migraine attacks in 7 of 12 (58%) participants with migraine, compared with none after placebo.12 Their reported median peak headache intensity stood at 2.5 (range, 0–10). This evidence concerns the gene ADCYAP1 and migraine disorder.